THERAPEUTIC STUDIES IN MURINE LUPUS

小鼠狼疮的治疗研究

• 批准号: 3810923
• 负责人: A D STEINBERG
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3810923
• 关键词: CD4 molecule; CD8 molecule; antibody; autoimmune disorder; connective tissue disorder chemotherapy; disease /disorder model; genetic strain; immunogenetics; immunopathology chemotherapy; infant animal; interleukin 4; laboratory mouse; leukocyte activation /transformation; nonhuman therapy evaluation; systemic lupus erythematosus; tumor necrosis factor alpha

Spontaneously autoimmune mouse strains provide good models for potential new therapies for humans with autoimmune diseases. We have repeated a prior study and have administered anti-IL 4 antibody to MRL-lpr/lpr mice from birth and again observed retarded from the development of lymphadenopathy. Anti-IL5 given to NZB mice from 2 weeks of age had no beneficial effect on IgM production.

自发自身免疫的小鼠品系为潜在的 治疗患有自身免疫性疾病的人类的新疗法。我们已经重复了一次 研究并给MRL-LPR/LPR小鼠注射了抗IL-4抗体。 出生后再次观察到发育迟缓的淋巴结病。 从2周龄开始给NZB小鼠注射抗IL5对小鼠的免疫功能无明显影响 IGM制作。